As part of its contribution to the fight against COVID-19, Sharp has donated 80 units of its FP-J30 air purifiers with Plasmacluster Technology to four hospitals in Singapore caring for COVID-19 patients. These hospitals include Changi General Hospital, Ng Teng Fong Hospital, Singapore General Hospital and more.
Taking the Fight to the Air
These air purifiers are recommended for a coverage area of 23 metres squared, around the size of a patient ward or staff lounge. SHARP air purifiers, with patented Plasmacluster Technology, have been providing clean and pure indoor air to users since its inception two decades ago. A joint study done by SHARP with Kitasako Institute in 2004 has confirmed that there was a dramatic reduction in bacteria and viruses in the presence of Plasmacluster Technology Ions. According to a joint research by SHARP Corporation and the Insitut Pasteur in Ho Chi Minh City, the Plasmacluster Technology can inhibit the infectiousness of the airborne avian influenza A (H7N9) virus by 99% in approximately 47 minutes.
The joint research is centred on the release of Plasmacluster Technology’s positively charged hydrogen (H+(H2O)m) and negatively charged oxygen ions (O2-(H2O)n) simultaneously into the air. These ions instantaneously bond on the surface of airborne substances such as viruses, becoming highly reactive OH radicals that break down the proteins on the surface of the viruses and inhibit the virus activity. This technology has the same inhibiting effects on other strains of influenza viruses including A/H1N1, H5N1, H7N9, FCoV (which belongs to the coronavirus group), and harmful microbes including E.Coli, MRSA, and TB.